Using clinical trial data to tailor adjuvant treatments for individual patients

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 98-104

  Regan, Meredith M ^a   Gelber, Richard D ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Chemotherapy; Endocrine therapy; Estrogen receptors; HER2; Progesterone receptors; STEPP; Subgroup analysis; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; LAPATINIB; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 35648964110     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.016     Document Type: Article

References (26)

1. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
2. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
3. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. for the HERA study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
4. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
5. Goldhirsch A., Coates A.S., Gelber R.D., et al. First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17 (2006) 1772-1776
6. BIG1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
7. Coates A.S., Keshaviah A., Thürlimann B., et al., for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
8. Viale G, Regan MM, Maiorano E, et al., for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: results from study BIG 1-98 J Clin Oncol, in press, doi:10.1200/JCO.2007.11.9453.
9. Piccart-Gebhart M.J., Perez E.A., Baselga J., et al. ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimization) study [BIG 2-06/N063D/EGF 106708]: a phase III study for HER2-overexpressing early breast cancer (BC). The Breast 16 Suppl. 1 (2007) S33 [Abstract P118]
10. Smith I, Procter M, Gelber RD, et al. for the HERA Study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007;369:29-36.
11. Peto R. Statistical aspects of cancer trials. In: Halnan K. (Ed). The treatment of cancer (1982), Chapman & Hall, London 867-871
12. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 365 (2005) 1308
13. Lagakos S.W. The challenge of subgroup analyses-reporting without distorting. N Engl J Med 354 (2006) 1667-1669
14. Simes R.J., and Zelen M. Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer. J Clin Oncol 3 (1985) 1418-1431
15. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
16. Bonetti M., and Gelber R.D. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19 (2000) 2595-2609
17. Bonetti M., and Gelber R.D. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5 (2004) 465-481
18. Regan M.M., Gelber R.D., and for the International Breast Cancer Study Group. Predicting response to systemic treatments; learning from the past to plan for the future. Breast 14 (2006) 582-593
19. Gunnarsdottir K., Jensen M.-B., Zahrieh D., et al. CEF is superior to CMF for tumors with topoisomerase IIα gene alterations; a STEPP (subpopulation treatment effect pattern plot) analysis on Danish Breast Cancer Cooperative Group study 89D. Breast Cancer Res Treat 100 Suppl. 1 (2006) S46 [Abstract 1023]
20. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 (2005) 1678-1717
21. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant polychemotherapy in oestrogen-receptor-poor breast cancer: meta-analysis of individual patient data from the randomized trials [in preparation].
22. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667
23. Venables WN, Ripley BD. Modern applied statistics with S, 4th ed. New York: Springer; 2002. p. 251-69.
24. Price K.N., and Goldhirsch A. Clinical trial update: International Breast Cancer Study Group. Breast Cancer Res 7 (2005) 252-254
25. Regan MM, Pagani O, Walley B, et al. Premenopausal endocrine-responsive breast cancer: For whom is chemotherapy chosen? [manuscript in preparation].
26. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. The Breast 10 Suppl 3 (2001) 130-138